PPF Bioventure Fund

PPF Bioventure Fund is the specialized venture capital and investment arm of the PPF Group, an international investment firm based in the Czech Republic. The fund focuses on the life sciences sector, particularly investing in innovative biotechnology companies developing novel therapies for oncology and immunology. Its most significant asset is SOTIO Biotech, which serves as the operational platform for the group's clinical development programs. The fund's strategy involves a combination of direct investments in early-stage biotechs and the strategic development of its own clinical-stage portfolio through SOTIO. Key programs in its portfolio include IL-15 superagonists, antibody-drug conjugates (ADCs), and CAR-T cell therapies targeting various solid tumors. Through its permanent capital base, the fund supports the advancement of high-potential medical innovations from early research to global commercialization.